Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

J. Ojha; C. Secreto; K. Rabe; J. Ayres-Silva; R. Tschumper; D. V. Dyke; S. Slager; R. Fonseca; T. Shanafelt; N. Kay; E. Braggio

doi:10.1038/leu.2014.226

Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

J. Ojha, C. Secreto, K. Rabe, J. Ayres-Silva, R. Tschumper, D. V. Dyke, S. Slager, R. Fonseca, T. Shanafelt, N. Kay, E. Braggio

Research output: Contribution to journal › Letter › peer-review

35 Scopus citations

Original language	English (US)
Pages (from-to)	2395-2398
Number of pages	4
Journal	Leukemia
Volume	28
Issue number	12
DOIs	https://doi.org/10.1038/leu.2014.226
State	Published - Dec 11 2014

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2014.226

Cite this

@article{0e1827e6c6bc4c0d901367e0236e39e7,

title = "Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression",

author = "J. Ojha and C. Secreto and K. Rabe and J. Ayres-Silva and R. Tschumper and Dyke, {D. V.} and S. Slager and R. Fonseca and T. Shanafelt and N. Kay and E. Braggio",

note = "Funding Information: RF has received a patent for the prognostication of MM based on genetic categorization of the disease. He has received consulting fees from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millenium and AMGEN. He also has sponsored research from Cylene and Onyx. TS was supported by fundings from Hospira, Genentech, Glaxo-Smith-Kline, Jannsen, Celgene and Cephalon. The remaining authors declare no conflcit of interest. Funding Information: EB is a recipient of the Marriott Specialized Workforce Development Awards in Individualized Medicine and the Henry Predolin Foundation Career Development Award. This work was supported by the Henry Predolin Foundation and grant NIH-CA95241.",

year = "2014",

month = dec,

day = "11",

doi = "10.1038/leu.2014.226",

language = "English (US)",

volume = "28",

pages = "2395--2398",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

AU - Ojha, J.

AU - Secreto, C.

AU - Rabe, K.

AU - Ayres-Silva, J.

AU - Tschumper, R.

AU - Dyke, D. V.

AU - Slager, S.

AU - Fonseca, R.

AU - Shanafelt, T.

AU - Kay, N.

AU - Braggio, E.

N1 - Funding Information: RF has received a patent for the prognostication of MM based on genetic categorization of the disease. He has received consulting fees from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millenium and AMGEN. He also has sponsored research from Cylene and Onyx. TS was supported by fundings from Hospira, Genentech, Glaxo-Smith-Kline, Jannsen, Celgene and Cephalon. The remaining authors declare no conflcit of interest. Funding Information: EB is a recipient of the Marriott Specialized Workforce Development Awards in Individualized Medicine and the Henry Predolin Foundation Career Development Award. This work was supported by the Henry Predolin Foundation and grant NIH-CA95241.

PY - 2014/12/11

Y1 - 2014/12/11

UR - http://www.scopus.com/inward/record.url?scp=84926984290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926984290&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.226

DO - 10.1038/leu.2014.226

M3 - Letter

C2 - 25034147

AN - SCOPUS:84926984290

SN - 0887-6924

VL - 28

SP - 2395

EP - 2398

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this